Rosiglitazone and cardiovascular risk

被引：110

作者：

Psaty, Bruce M. ^{[1
]}

Furberg, Curt D.

机构：

[1] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA

[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[3] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA

[4] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA

[5] Wake Forest Univ, Div Publ Hlth Sci Sci, Winston Salem, NC 27109 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 356卷 / 24期

关键词：

D O I：

10.1056/NEJMe078099

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2522 / 2524

页数：3

共 20 条

[1]

[Anonymous], LANCET

[2]

BACIU A, 2007, FUTURE DRUG SAFETY P

[3] Thiazolidinediones in type 2 diabetes mellitus - Current clinical evidence [J].

Diamant, M ;

Heine, RJ .

DRUGS, 2003, 63 (13) :1373-1405

[4]

*FOOD DRUG ADM, 2007, FED REGISTER, V72, P5069

[5] Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].

Gerstein, H. C. ;

Yusuf, S. ;

Holman, R. R. ;

Bosch, J. ;

Anand, S. ;

Avezum, A. ;

Budaj, A. ;

Chiasson, J. ;

Conget, I. ;

Dagenais, G. ;

Davis, M. ;

Diaz, R. ;

Dinccag, N. ;

Enjalbert, M. ;

Escalante, A. ;

Fodor, G. ;

Hanefeld, M. ;

Hedner, T. ;

Jolly, K. ;

Keltai, M. ;

Laakso, M. ;

Lanas, F. ;

Lonn, E. ;

McQueen, M. ;

Mohan, V. ;

Phillips, A. ;

Piegas, L. ;

Pirags, V. ;

Probstfield, J. ;

Shaw, J. ;

Schmid, I. ;

Teo, K. ;

Zimmet, P. ;

Zinman, B. ;

Gerstein, H. C. ;

Yusuf, S. ;

Bosch, J. ;

Pogue, J. ;

Sheridan, P. ;

Dinccag, N. ;

Hanefeld, M. ;

Hoogwerf, B. ;

Laakso, M. ;

Mohan, V. ;

Shaw, J. ;

Zinman, B. ;

Holman, R. R. ;

Diaz, R. ;

Ahuad Guerrero, R. ;

Albisu, J. .

LANCET, 2006, 368 (9541) :1096-1105

[6]

McAdam BF, 1999, P NATL ACAD SCI USA, V96, P5890

[7] Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2 [J].

McAdam, BF ;

Catella-Lawson, F ;

Mardini, IA ;

Kapoor, S ;

Lawson, JA ;

FitzGerald, GA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :272-277

[8] Thiazolidinediones for initial treatment of type 2 diabetes? [J].

Nathan, David M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2477-2480

[9] Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J].

Nathan, DM ;

Cleary, PA ;

Backlund, JYC ;

Genuth, SM ;

Lachin, JM ;

Orchard, TJ ;

Raskin, P ;

Zinman, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2643-2653

[10] Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus [J].

Nissen, SE ;

Wolski, K ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (20) :2581-2586

← 1 2 →